Mama’s Creations, Inc. (MAMA), a prominent player in the fresh deli-prepared food market, achieved strong results for Q2 2024, highlighted by 14% revenue growth to $28.4 million and significant retail placements in Walmart and Costco.
CEO Adam Michaels attributes this success to the company’s commitment to the “4 Cs”—Cost, Controls, Culture, and Catapult—and an aggressive operational strategy designed to enhance margins and drive profitability.
Key Financial Highlights
For Q2 2024, Mama’s Creations saw revenues increase by 14%, reaching $28.4 million. This growth stems from successful pricing strategies, increased product demand, and expanded retail partnerships.
Gross profit totaled $6.9 million, reflecting a 24.2% gross margin compared to 30.3% in Q2 2023, with margins impacted by high commodity costs and construction-related expenses.
The company’s net income reached $1.1 million, or $0.03 per diluted share, compared to $1.7 million or $0.05 per share in the prior year’s quarter.
CHECK THIS OUT: BayCom (BCML) Q3 2024 Earnings: Strong Growth Amid Market Challenges
Key Developments and Operational Achievements
Mama’s Creations achieved a major milestone by securing placements in 2,000 Walmart locations and a national Costco deal.
Walmart introduced two new SKUs nationwide, while Costco’s National Buy includes Mama’s 3-lb meatball sleeve in six regions, marking new expansions in Texas and the Southeast.
These partnerships are expected to significantly elevate brand visibility and drive revenue in the coming quarters.
Strategic CapEx Investments for Long-Term Efficiency
Mama’s invested $3.5 million in CapEx projects aimed at optimizing operations, particularly in chicken processing, which will more than double production capacity.
The CapEx projects, though temporarily impacting margins, are set to enhance efficiency, reduce labor costs, and avoid third-party upcharges.
By Q4 2024, Mama’s expects margins to stabilize as these improvements take full effect, positioning the company for sustainable growth.
Leadership Enhancements and Industry Presence
The appointment of Skip Tappan as Chief Operating Officer strengthens Mama’s supply chain management.
With 30+ years of experience at companies like Walmart and Campbell Soup, Tappan will focus on optimizing operations, enhancing asset utilization, and expanding the company’s reach.
Mama’s also amplified its presence at trade shows, leading to new placements and heightened interest from potential retailers, including Walmart.
Market Position and Industry Relevance
Mama’s Creations strategically positions itself to capitalize on rising consumer demand for fresh, high-quality deli-prepared foods, as consumers increasingly prefer convenience and freshness.
With increased capacity from its recent CapEx projects, Mama’s can cater to high-volume retailers like Costco while maintaining profitability.
Industry-wide, rising commodity costs, especially in chicken, are pressuring margins; however, Mama’s proactive pricing and operational efficiencies help shield the company from volatility.
The successful placements in Walmart and Costco demonstrate Mama’s ability to meet large-scale retail demands.
CEO Adam Michaels anticipates that these partnerships will not only enhance revenue but also establish Mama’s as a reliable supplier to major retailers nationwide, fostering long-term growth and market penetration.
Driving Profitability and Margin Expansion
Mama’s Creations remains focused on its 4 Cs strategy, with initiatives underway to restore and enhance margin profiles.
By Q4, with CapEx projects completed, Mama’s expects to see improved margins and increased revenue from new product placements.
The company’s goal is to achieve high ROI trade promotions, reaching a long-term target of 10% of revenue allocated to marketing.
With favorable macroeconomic trends in the deli-prepared foods sector, Mama’s is positioned for a transformative year ahead, especially with expanded capacity and national retail partnerships.
READ ALSO: D-Wave Quantum (QBTS) Reports Strong Q2 with 28% Revenue Growth and Checkpoint’s Cosibelimab Shows Promising Results for Advanced Skin Cancer.
